Munich Leukemia Laboratory Selects IBM Watson and Illumina for Research Collaboration to Advance Diagnostics and Develop Personalized Treatment Tools for Leukemia & Lymphoma

IBMMunich Leukemia Laboratory (MLL), a state-of-the-art leukemia and lymphoma diagnostic and research laboratory based in Munich, has teamed up with IBM (NYSE: IBM) and Illumina, Inc. (NASDAQ: ILMN) to help build a new cognitive technology prototype that aims to help researchers improve leukemia treatment.

The prevalence of leukemia is on the rise in Europe, with 15,000 new diagnoses each year in Germany alone.(1) MLL will use NovaSeq technology from Illumina, the global leader in next-generation sequencing technology, to sequence samples from its biobank of more than 500,000 cases. MLL researchers then plan to use Watson to help analyze the genomic data alongside other data sources. The project intends to include innovative testing processes such as automated phenotyping and genotyping including whole genome sequencing (WGS) and transcriptome sequencing (RNASeq) in 5,000 cases.

The ultimate goal is to develop a Watson-based technology prototype that can help analyze genomic and phenotypic data alongside medical literature, guidelines and study results, providing clinicians with information relevant to leukemia care. Following successful development, the tool could also be made available to other laboratories in the future.

Prof. Torsten Haferlach, co-founder and CEO of MLL, states, "We at MLL are excited to combine our data and knowledge, IBM's cognitive computing tools, and Illumina's new sequencing platform to create a new era of insights in leukemia biology that will also drive more personalized treatment strategies."

"As a company committed to improving human health, we are delighted to welcome MLL as our first European customer to adopt the NovaSeq platform," said Paula Dowdy, Senior Vice President and General Manager, Illumina, Europe, Middle East, and Africa. "MLL's strategic decision to create a future path for whole-genome sequencing to help promote better health outcomes, reflects one of Illumina’s key strategies to connect genomics to the everyday lives of those living with cancer."

MLL will utilize Illumina's BaseSpace® Informatics Suite to be able to streamline data analysis, storage, data curation and aggregation. The BaseSpace Sequence Hub Frankfurt site will help MLL manage the data as the project scales and facilitates data transfer to IBM Watson. Additional tertiary analysis with BaseSpace Cohort Analyzer and BaseSpace Correlation Engine allows MLL's genomic data to be combined with other clinical data to enhance interpretation results.

"Cognitive computing is critical to help providers unlock the insights hidden in large data pools and scale their expertise in a global market through digital services," said Bart de Witte, director of digital health, IBM. "This research collaboration is indicative of the growing global market to create and implement new cognitive approaches to data-driven challenges for health systems that are increasingly overwhelmed by data."

About MLL
The Munich Leukemia Laboratory was founded in 2005 to take diagnostic responsibility for patients with leukemia and lymphoma for both in-patient and out-patient settings. The team of 150 hematologists, researchers and technicians works to optimize and refine diagnostics, including automation of laboratory procedures and improvements according to the established norms of EN ISO 15189 as well as national and international involvement in scientific projects and research trials. MLL is committed to expanding and improving high-quality diagnostics of hematological neoplasms, at the highest scientific and technical levels.

About IBM
IBM Watson is the first commercially available cognitive computing capability representing a new era in computing. The system, delivered through the cloud, analyzes high volumes of data, understands complex questions posed in natural language, and proposes evidence-based answers. Watson continuously learns, gaining in value and knowledge over time, from previous interactions. The IBM Watson Health unit helps improve the ability of doctors, researchers and insurers to innovate by surfacing insights from the massive amount of personal health data being created and shared daily.

About Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

1. European Leukemia Network.

Most Popular Now

Hull University Teaching Hospitals NHS T…

Hull University Teaching Hospitals NHS Trust has deployed DXC Technology's (NYSE:DXC) cloud-based Clinical Aide mobile application, which both improves secure access to electronic patient medical records and increases patient and...

Central Hospital in Finland Automates Sy…

This November Central Ostrobothnia Central Hospital in Finland has started symptom tracking and remote monitoring of corona virus-infected patients with the Buddy Healthcare mobile application and clinical monitoring platform. The...

Ultrapotent COVID-19 Vaccine Candidate D…

An innovative nanoparticle vaccine candidate for the pandemic coronavirus produces virus-neutralizing antibodies in mice at levels ten-times greater than is seen in people who have recovered from COVID-19 infections. Designed...

Interactive virtual reality emerges as a…

Bristol scientists have demonstrated a new virtual reality [VR] technique which should help in developing drugs against the SARS-CoV-2 virus - and enable researchers to share models and collaborate in...

Softphone App to Save NHS up to £20 Mill…

GPs and patients are to benefit from a new softphone app that will eliminate almost all the "hidden cost" of calls for remote consultations and is forecast to save the...

More than 1,000 Exhibitors have Already …

16 - 19 November 2020, Düsseldorf, Germany. This year, the world's largest and leading medical trade fair, MEDICA, and the number one international event for the medical technology manufacturing supplier market...

DMEA Newcomer Award: The Search is on fo…

13 - 15 April 2021, Berlin, Germany. More efficient, digital and patient-friendly! Tomorrow's healthcare system promises great things. And to ensure this becomes reality a fresh impetus and creative ideas are...

App to Help NHS Prevent Deadly Hospital …

Compass app to help NHS trusts prevent hospital-acquired acute kidney injury and pneumonia - both of which cause harm to COVID-19 patients and can be fatal. Hospitals could alleviate pressure...

Leeds Deploys Imaging Tech for Advanced …

A multi-million pound initiative that is digitising, connecting and applying artificial intelligence to NHS pathology services in the North of England has taken an important step, after Leeds Teaching Hospitals...

Survey of COVID-19 Research Provides Fre…

Researchers at Karolinska Institutet in Sweden have explored all COVID-19 research published during the initial phase of the pandemic. The results, which were achieved by using a machine learning-based approach...

South Tees Signs Major Deal with Alcidio…

South Tees Hospitals NHS Foundation Trust has signed a major deal with smart health technology provider Alcidion. An entire range of new technology capabilities will alleviate pressure for busy NHS...